Good evening :)
$
₹
Electrocore LLC

Electrocore LLC

ECOR

NASDAQ
Asset Logo

Electrocore LLC

ECOR

NASDAQ
$7.465.94% (+0.41)
$
₹
$7.465.94% (+0.41)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $63.6M the stock is ranked 4936

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

34.88
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.65
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-39.96%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+171.91%

Earnings Growth

+16.61%

Rev. Growth

+30.85%

See Detailed Forecast

Company Profile

Company Profile

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 171.91% growth, versus a trailing 3-year CAGR of 8.76%.

2026
Current$7.05Baseline
Analyst Target - 1 year
Target$19.17+171.91%

All values in $

202220232024202520262027$7.87$12.28$16.68Target+171.91%
2026
Current$7.05Baseline
Analyst Target - 1 year
Target$19.17+171.91%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 30.85% growth, versus a trailing 3-year CAGR of 55.06%.

2025
Current$32.03Baseline
Forecast for Dec 2026
High$42.88+33.89%
Average$41.91+30.85%
Low$41.37+29.16%

All values in $ Million

2021202220232024202520265.458.5916.0325.1832.03Low+29.16%Average+30.85%High+33.89%
2025
Current$32.03Baseline
Forecast for Dec 2026
High$42.88+33.89%
Average$41.91+30.85%
Low$41.37+29.16%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.65Baseline
Forecast for Dec 2026
High$-1.24+24.85%
Average$-1.38+16.61%
Low$-1.48+10.3%

All values in $

202120222023202420252026-4.79-4.79-3.48-1.62-1.65Low+10.3%Average+16.61%High+24.85%
2025
Current$-1.65Baseline
Forecast for Dec 2026
High$-1.24+24.85%
Average$-1.38+16.61%
Low$-1.48+10.3%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

8.6
-3.4
9.2
-3
9.5
-5.2
9.4
-3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue5.446.136.557.046.717.388.689.249.589.45
Net Income-3.50-2.65-2.49-3.22-3.85-3.67-3.40-3.03-5.27-3.05
Net Profit Margin-64.41%-43.24%-38.09%-45.81%-57.37%-49.73%-39.18%-32.83%-54.99%-32.37%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Electrocore LLC -34.88-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ECOR with any stock or ETF
Compare ECOR with any stock or ETF
Comparing from
ECOR
ABT
DHR
Loading...

Frequently asked questions

  1. Electrocore LLC (ECOR) share price today is $7.46 as of October 26, 2026 at 11:14 PM IST. The stock touched a day high of $7.46 and a day low of $7.04.

  2. Electrocore LLC stock trades on NASDAQ under the ticker symbol ECOR.

  3. Electrocore LLC's market capitalization is $63.56M as of October 26, 2026 at 11:14 PM IST.

  4. Electrocore LLC's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Electrocore LLC's price-to-book (P/B) ratio is 34.88 as of October 26, 2026.

  6. Yes, You can buy Electrocore LLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Electrocore LLC shares in three steps: 1. Search Electrocore LLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Electrocore LLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Electrocore LLC (ECOR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.3388 shares at the current price of $7.46.

Loading...